Page 2 - Dr Reddy’s

Inflows in Tata Motors stock may surge as it replace Dr Reddy's in Sensex

Change effective from Dec 19, but adjustment will take place on Dec 16. After DRL's deletion, Sun Pharma will be the only healthcare stock in the index

Stocks to watch: SBI, DRL, Britannia, Coal India, Divi's Lab, Paytm, ABFRL

Stocks to watch today: Coal India, Divi's Lab will report the July-September quarter (Q2FY23) results on Monday, November 7; SBI's net profit climbed 73.9 per cent YoY to Rs 13,265 crore in Q2FY23

Wockhardt likely to sell India business to cut debt, focus on UK: Analysts

Company left with low-margin brands in India after selling profitable ones

Stocks to Watch: Torrent Pharma, ONGC, Dr Reddy's, BHEL, BPCL, Birla Corp

Stocks to Watch: Dr Reddy's has received US FDA nod for marketing Timolol Maleate, which is used to treat Glaucoma

Stocks to Watch: NDTV, Dr.Reddy's, IndiGo, SBI, Zee, Consumer Firms

Stocks to Watch Today: NDTV open offer to start from October 17. IndiGo's co-promoter Rakesh Gangwal likely to sell up to 2.8 per cent stake in open market.

Stocks to watch: Titan, Dr Reddy's, Nelco, IOC, GIC Housing, Torrent Pharma

Stocks to watch today: Titan plans to add 20 to 30 Tanishq stores over two to three years in the Middle East and North America; Nelco inked pact with Intelsat to provide inflight connectivity services

Stocks to Watch: YES Bank, Cipla, Bank of Baroda, Zomato, HDFC, ITC, NTPC

Stocks to Watch today: ITC, UPL, Zomato, Arvind, Bajaj Consumer Care, among others will release their Q1 earnings today.

Dr Reddy's says it aims to triple reach to 1.5 bn patients by 2030

Under its sustainability goals for the next decade, Dr Reddy's said it is making its "products accessible and affordable for patients" and "25 per cent of new launches to be first to market by 2027"

Launches, base biz expansion tonic for Dr Reddy's double-digit growth

While the company's bottom line grew 10.5% annually over the 2016-17 through 2021-22 (FY22) period, it is expected to register thrice that growth rate over next two years, observes ICICI Securities

Markets post best daily gains in three months; Sensex, Nifty soar nearly 3%

China rate cut helps improve sentiment

Dr Reddy's Q4 PAT falls 76% YoY on impairment costs; misses estimates

The company's board also recommended a final dividend of Rs 30 per equity share of face value of Rs. 5 each for the financial year 2021-22.

Stocks to Watch: ITC, Lupin, Ruchi Soya, Manappuram Finance, JSW, Biocon

Stocks to Watch: The US markets suffered the biggest one-day sell-off in almost two years -Investors worry about inflation and its impact on earnings and prospects for monetary policy tightening

Dr Reddy's Q4 PAT may rise 28% YoY; margins likely to fall, say analysts

The pharmaceutical giant may witness some impact due to its large exposure of the business to Russia, and CIS regions.

Stocks to Watch: RIL, HUL, Dr.Reddy's, PNB Housing, Future Retail, Banks

Reliance Industries is likely to be in limelight as the company is looking to take advantage of the surging diesel demand in Europe in the backdrop of Russia-Ukraine conflict.

Sell-off toll! HDFC twins, HUL, Dr.Reddy's among Nifty50 stks at 52-wk lows

Apart from the 8 stocks among the Nifty50 index, a total of 26 stocks too dropped to their respective 52-week lows among the Nifty500 index.

Russia-Ukraine crisis: Indian pharma exporters in wait and watch mode

An official of Dr Reddy's Laboratories said they are closely monitoring the developments and ensuring the well-being of their staff in that region is the first and foremost priority

Binnopharm to acquire 2 anti-bacterial brands from Dr Reddy's

During the transition period, Dr Reddy's will continue to supply the product to Binnopharm Group to ensure availability in the market

Stocks to Watch: DRL, Mankind, Sun Pharma, Wipro, Kalpataru, TTML, Airlines

Ambuja Cement, Nestle India and Veritas to announce December quarter results today.

Dr Reddy's to launch Molflu at Rs 35 per capsule for Covid treatment

The overall cost for a patient treated with a 5-day course of 40 capsules of the generic drug, to be sold under brand name 'Molflu', will come up to Rs 1,400

Dr Reddy's inks pact with Citius Pharma to sell rights to anti-cancer agent

The drug firm said it has entered into a definitive agreement with Citius to sell all of its rights to E7777 and certain related assets.